Celltrion Sets Out Timetable For Omalizumab Trials
Celltrion has set out a development timetable for its biosimilar omalizumab candidate that includes finishing a Phase III trial by 2022.
Celltrion has set out a development timetable for its biosimilar omalizumab candidate that includes finishing a Phase III trial by 2022.